Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Bayer Aktienges ADR (BAYRY)
Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 54,897,912
  • Shares Outstanding, K 3,929,700
  • Annual Sales, $ 53,468 M
  • Annual Income, $ 4,373 M
  • 60-Month Beta 1.21
  • Price/Sales 1.04
  • Price/Cash Flow 4.91
  • Price/Book 1.32
Trade BAYRY with:
  • Price/Earnings ttm 7.22
  • Earnings Per Share ttm 1.93
  • Most Recent Earnings 0.79 on 05/11/23
  • Next Earnings Date 05/09/23
  • Annual Dividend & Yield 0.45 (3.24%)
  • Most Recent Dividend 0.451 on 05/02/23
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 0.44
  • Number of Estimates 2
  • High Estimate 0.47
  • Low Estimate 0.41
  • Prior Year 0.51
  • Growth Rate Est. (year over year) -13.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.6800 unch
on 06/09/23
16.1500 -15.29%
on 05/10/23
-2.3395 (-14.60%)
since 05/09/23
3-Month
13.6800 unch
on 06/09/23
17.0000 -19.53%
on 04/14/23
-1.5800 (-10.35%)
since 03/09/23
52-Week
11.4100 +19.89%
on 09/28/22
17.0000 -19.53%
on 04/14/23
-3.6660 (-21.13%)
since 06/09/22

Most Recent Stories

More News
2 No-Brainer Stocks to Buy Right Now for Less than $30

Two big companies that are worth investing in have low share prices but big dividends.

BAYRY : 13.6800 (-2.08%)
MPW : 9.19 (-1.71%)
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

REGN : 746.52 (-0.48%)
SNY : 51.24 (-0.58%)
RHHBY : 39.1500 (-0.63%)
BAYRY : 13.6800 (-2.08%)
ROTH MKM's Agribusiness Investment Banking Group Sees Success with the Closing of Three M&A Sellside Transactions

ROTH MKM (“Roth”), www.roth.com , a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group...

CTVA : 56.44 (-2.40%)
MBII : 0.7981 (-20.19%)
BIOX : 12.08 (-0.41%)
BAYRY : 13.6800 (-2.08%)
BG : 93.62 (+2.68%)
CVX : 158.86 (-0.24%)
Unity (UNX) Down on Disappointing Results From Wet AMD Study

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

REGN : 746.52 (-0.48%)
BAYRY : 13.6800 (-2.08%)
UBX : 3.44 (-2.82%)
Regeneron (REGN) Gets Label Extension for Cholesterol Drug

Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.

REGN : 746.52 (-0.48%)
SNY : 51.24 (-0.58%)
BAYRY : 13.6800 (-2.08%)
Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?

Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.

REGN : 746.52 (-0.48%)
SNY : 51.24 (-0.58%)
BAYRY : 13.6800 (-2.08%)
Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

REGN : 746.52 (-0.48%)
NVS : 100.93 (+0.28%)
JNJ : 160.01 (-0.16%)
BAYRY : 13.6800 (-2.08%)
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review

Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.

REGN : 746.52 (-0.48%)
ALNY : 190.83 (+0.21%)
BAYRY : 13.6800 (-2.08%)
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRK : 110.71 (+0.35%)
BAYRY : 13.6800 (-2.08%)
MRNA : 123.26 (-1.34%)
ALLO : 5.64 (-2.76%)
Verona (VRNA) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.

ALKS : 31.13 (-1.30%)
BAYRY : 13.6800 (-2.08%)
VRNA : 21.15 (+0.24%)
ALLO : 5.64 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 13.8633
2nd Resistance Point 13.8267
1st Resistance Point 13.7533
Last Price 13.6800
1st Support Level 13.6433
2nd Support Level 13.6067
3rd Support Level 13.5333

See More

52-Week High 17.0000
Fibonacci 61.8% 14.8646
Fibonacci 50% 14.2050
Last Price 13.6800
Fibonacci 38.2% 13.5454
52-Week Low 11.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar